TargetMol

Quininib

Product Code:
 
TAR-T28487
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28487-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28487-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28487-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Quininib is a regulator of Ocular Angiogenesis. Quininib significantly inhibits angiogenic tubule formation in HMEC-1 cells, angiogenic sprouting in aortic ring explants and retinal revascularisation in OIR mice.
CAS:
143816-42-6
Formula:
C17H13NO
Molecular Weight:
247.297
Purity:
0.98
SMILES:
Oc1ccccc1C=Cc1ccc2ccccc2n1

References

1. Butler CT, Reynolds AL, Tosetto M, Dillon ET, Guiry PJ, Cagney G, O'Sullivan J, Kennedy BN. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292(9):3552-3567. doi: 10.1074/jbc.M116.747766. Epub 2016 Dec 29. PubMed PMID: 28035003; PubMed Central PMCID: PMC5339742. 2. Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, Reynolds AL, Sheahan K, O'Donoghue D, Gallagher WM, Fennelly D, Kennedy BN, O'Sullivan J. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. Sci Rep. 2016 Oct 14;6:34523. doi: 10.1038/srep34523. PubMed PMID: 27739445; PubMed Central PMCID: PMC5064353. 3. Galvin O, Srivastava A, Carroll O, Kulkarni R, Dykes S, Vickers S, Dickinson K, Reynolds AL, Kilty C, Redmond G, Jones R, Cheetham S, Pandit A, Kennedy BN. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo. J Control Release. 2016 Jul 10;233:198-207. doi: 10.1016/j.jconrel.2016.04.004. Epub 2016 Apr 13. PubMed PMID: 27086168. 4. Reynolds AL, Alvarez Y, Sasore T, Waghorne N, Butler CT, Kilty C, Smith AJ, McVicar C, Wong VH, Galvin O, Merrigan S, Osman J, Grebnev G, Sj?lander A, Stitt AW, Kennedy BN. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. J Biol Chem. 2016 Apr 1;291(14):7242-55. doi: 10.1074/jbc.M115.710665. Epub 2016 Feb 4. PubMed PMID: 26846851; PubMed Central PMCID: PMC4817159.